L'intérêt à découvert pour Invivyd donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Invivyd. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Invivyd (NASDAQ:IVVD) Stock, Rapport sur les intérêts à découvert

INVIVYD INC

Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Invivyd Inc

Keybanc analyst Sophie Karp downgrades Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) from Sector Weight to Underweight and announces $90 price target.

News

Downgrades

Price Target

Analyst Ratings

Keybanc Downgrades Consolidated Edison to Underweight, Announces $90 Price Target

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), adding that the stock <a href="https://www.benzinga.com/quote/SOFI/earnings">goes to &#8220;new highs.&#8221;</a>
To support his view, the company reported quarterly adjusted sales of $770.72 million on April 29, beating analyst estimates of $739.04 million. The company also reported quarterly adjusted earnings of 6 cents per share, beating analyst estimates of 4 cents per share.
Cramer said Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) has &#8220;some upside because they are doing some pretty terrific things in streaming, so I'm ok with it.&#8221;
On the earnings front, Roku posted better-than-expected results for the first quarter on May 1.
Cramer recommended not buying GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>). &#8220;It's inconsistent and too controlled by China, not America. So, I am not going to be a backer,&#8221; he added.
As per the recent news, GE HealthCare announced FDA approval for Optison Ultrasound Enhancing Agent.
&#8220;The beer business is soft, the spirits business is not so good, and, frankly, I expected more from the company. I think the company has been a very big disappointment,&#8221; Cramer said when asked about Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>). &#8220;I don't need to be in stocks that have been disappointing.&#8221;
Supporting his view, RBC Capital analyst Nik Modi lowered the price target on the stock from $289 to $233 on April 14.
Price Action:
<ul class="wp-block-list">
<li>SoFi shares gained 1.8% to settle at $14.29 on Tuesday.</li>
<li>Roku shares rose 3.8% to close at $71.40 during the session.</li>
<li>GE Healthcare shares fell 0.4% to settle at $73.83 on Tuesday.</li>
<li>Constellation Brands shares declined 1.2% to settle at $187.67 on Tuesday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45373483/top-2-materials-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Materials Stocks That May Keep You Up At Night In May</a></li>
</ul>
Photo: Shutterstock

Markets

Media

GEHC

ROKU

SOFI

Jim Cramer: SoFi Goes To 'New Highs,' Recommends Not Buying This Health Care Stock

WIIM

KVYO

Klaviyo shares are trading lower after the company announced a proposed $372 million secondary offering.

Keybanc analyst Sophie Karp upgrades Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) from Sector Weight to Overweight and announces $103 price target.

Upgrades

Keybanc Upgrades Ameren to Overweight, Announces $103 Price Target

Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) reported quarterly losses of $(1.55) per share. This is a 79.42 percent increase over losses of $(7.53) per share from the same period last year.

Earnings

TOVX

Theriva Biologics Q1 EPS $(1.55) Up From $(7.53) YoY

Tencent Music shares are trading higher following Q1 reported financial results.

Nu Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization), for a Food and Drug Administration (FDA) requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
The Company is currently working on a separate IND-enabling Good Laboratory Practice (GLP) -compliant toxicology and toxicokinetic study of SPC-15.&nbsp; Positive preclinical data from these studies, if achieved, would support an IND submission for SPC-15 in 2025. Should Silo receive approval of the IND, Silo would proceed to a first-in-human Phase 1 clinical trial for SPC-15.
Columbia University, the Company's collaboration partner for pre-clinical development, granted Silo an exclusive global license to further develop, manufacture, and commercialize SPC-15 worldwide.
 &nbsp;
 &nbsp;

SILO

Silo Pharma Agrees With Frontage Laboratories For FDA Requested 7-Day Safety And Toxicology Large Animal Study Of Lead Asset SPC-15, Intranasal Prophylactic Treatment For PTSD

REBN

Reborn Coffee Signs MoU With Tori AI To Implement Smart Retail Technology

Renowned economist Peter Schiff has issued a stark warning about the U.S. trade deficit, asserting that without the implementation of high tariffs, the only path to significantly reduce the deficit is through a major decline in the value of the U.S. dollar.
What Happened: In a post on X, Schiff highlighted the potential economic consequences of current trade policies, predicting that a minor decline in the dollar would not only fail to address the deficit but could exacerbate it by increasing the cost of imports.
This, he warns, would inevitably lead to higher inflation and rising interest rates, posing significant challenges to the U.S. economy.
"Without very high tariffs, the only way to significantly reduce the U.S. trade deficit is with a major decline in the dollar," Schiff wrote on X. "A minor decline would just make the trade deficit larger by increasing the cost of imports. The consequence is both inflation and interest rates will rise."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Without very high tariffs the only way to significantly reduce the U.S. trade deficit is with a major decline in the dollar. A minor decline would just make the trade deficit larger by increasing the cost of imports. The consequence is both inflation and interest rates will rise.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1922608317320290695?ref_src=twsrc%5Etfw">May 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
After Donald Trump&#8216;s 2018 term, a 2023 U.S. International Trade Commission <a href="https://taxfoundation.org/research/all/federal/trump-tariffs-trade-war/">report found</a> that Trump's tariffs, which aimed to reduce the trade deficit by protecting domestic industries, resulted in a $3.4 billion production decrease in downstream industries due to higher input costs. 
These losses largely offset any gains in protected sectors, suggesting that tariffs alone may not be a silver bullet for addressing trade imbalances.
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45403100/bullish-for-nvidia-tesla-palantir-microsoft-alphabet-amazon-ai-revolution-is-coming-to-the-saudi-kingdom-says-wedbushs-dan-ives">&#8216;Bullish For Nvidia, Tesla, Palantir, Microsoft, Alphabet, Amazon:&#8217; AI &#8216;Revolution Is Coming&#8217; To The Saudi Kingdom, Says Wedbush&#8217;s Dan Ives</a>
Why It Matters: The broader economic context adds weight to Schiff's concerns. A January 2024 International Monetary Fund (IMF)<a href="https://www.imf.org/en/Publications/WP/Issues/2024/01/19/The-Macroeconomic-Consequences-of-Import-Tariffs-and-Trade-Policy-Uncertainty-543877"> paper revealed</a> that unexpected tariff shocks tend to reduce imports more than exports, leading to slight decreases in the trade deficit but at the expense of persistent GDP losses. 
The study estimated that reversing the 2018–2019 tariffs could increase U.S. output by 4% over three years, underscoring the trade-offs involved in protectionist policies.
This comes after the U.S. and China <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">reached a 90-day truce</a>, pausing the reciprocal tariffs on Monday this week. 
Price Action: Gold Spot US Dollar fell 0.72% to hover around $3,226.84 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.42% at the 100.5780 level.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Wednesday. The SPY was up 0.22% to $588.14, while the QQQ advanced 0.37% to $517.49, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest" target="_blank" rel="noreferrer noopener">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of ‘Compound Interest'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Commodities

Forex

Economics

ETFs

General

Peter Schiff Warns Only Major Dollar Decline Or High Tariffs Can Cut US Trade Deficit — But Inflation And Rates Will Soar

FRSX

Foresight Autonomous Holdings Agrees For POC Project With Global Tier One Automotive Supplier To Improve Urban Transit Safety Through Precision Curb Detection System

Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $(8.58) by 102.8 percent. This is a 91.27 percent decrease over earnings of $2.75 per share from the same period last year. The company reported quarterly sales of $5.58 million which beat the analyst consensus estimate of $5.50 million by 1.45 percent. This is a 40.55 percent decrease over sales of $9.39 million the same period last year.

Earnings Beats

ALUR

Allurion Technologies Q1 Adj. EPS $0.24 Beats $(8.58) Estimate, Sales $5.58M Beat $5.50M Estimate

Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) will release its second-quarter earnings results before the <a href="https://www.benzinga.com/quote/DE/earnings">opening bell on Thursday, May 15.</a>
Analysts expect the Moline, Illinois-based company to report quarterly earnings at $5.64 per share, down from $8.53 per share in the year-ago period. According to data from Benzinga Pro, Deere projects quarterly revenue at $10.79 billion, compared to $13.61 billion a year earlier.
On April 22, Oppenheimer analyst Kristen Owen maintained Deere with an Outperform rating and raised the price target from $510 to $513.
With the recent buzz around Deere, some investors may be eyeing potential gains from the company's dividends. As of now, Deere offers an annual dividend yield of 1.30%. That&#8217;s a quarterly dividend of $1.62 per share ($6.48 a year).  So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $461,676 or around 926 shares. For a more modest $100 per month or $1,200 per year, you would need $92,235 or around 185 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($6.48 in this case). So, $6,000 / $6.48 = 926 ($500 per month), and $1,200 / $6.48 = 185 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
DE Price Action: Shares of Deere, which operates under the brand name John Deere, gained 0.6% to close at $498.57 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a></li>
</ul>
Image: Shutterstock

Long Ideas

Trading Ideas

How To Earn $500 A Month From Deere Stock Ahead Of Q2 Earnings

NETSOL Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTWK#NASDAQ">NTWK</a>) reported quarterly earnings of $0.12 per share. This is a 300 percent increase over earnings of $0.03 per share from the same period last year. The company reported $17.53 million in sales this quarter. This is a 13.38 percent increase over sales of $15.46 million the same period last year.

NTWK

NETSOL Technologies Q3 EPS $0.12 Up From $0.03 YoY, Sales $17.53M Up From $15.46M YoY

Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>), a leader in enterprise AI-powered cloud data management, today announced a strategic agreement with Microsoft. This milestone extends the long-standing collaboration between the two companies, continuing innovation and customer adoption on the Microsoft Azure cloud platform. The announcements were made at Informatica World, the company's annual data management and AI conference held in Las Vegas.
Informatica and Microsoft are working closely to deliver unified, AI-powered solutions that combine Informatica's Intelligent Data Management Cloud&#x2122; platform with key Microsoft services, including Microsoft Fabric and Microsoft Azure. Informatica's cloud data management platform is available as a SaaS offering on Azure and via Azure Marketplace, enabling customers to build a trusted, secure and innovative data foundation to power their analytics and AI-driven business transformations.

INFA

Informatica Enters Into New Strategic Agreement With Microsoft To Accelerate Customer Adoption, Continuing Innovation And Customer Adoption On The Microsoft Azure Cloud Platform

Newly granted patent is part of the expanding intellectual property portfolio directed to:
-generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and
-incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jPx2ufkMgU0msrd130bt97ODr8ugiUJEn3waONvhWdO81_Tm48fKEVz6J_0WsDT09f-bPr0glnd07_FmMGH1e8p2YsmA3yRAYQrFNs8tWTY=">Surrozen, Inc.</a> ("Surrozen" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced the issuance of U.S. Patent No. 12,297,278.

SRZN

Surrozen Granted US Patent To Antibody-Based Molecules Targeting Key Receptors In Wnt Pathway

Wells Fargo analyst Stan Berenshteyn upgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Equal-Weight to Overweight and raises the price target from $31 to $35.

OMCL

Wells Fargo Upgrades Omnicell to Overweight, Raises Price Target to $35

Brag House Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) ("Brag House" or the "Company"), the premier Gen Z engagement platform that operates at the intersection of gaming, college sports, and social interaction, today announced an update on its investigation into recent trading activity in its stock. With assistance from its outside advisors, the Company's investigation has identified preliminary data suggesting the Company may have been the subject of illegal naked short selling. Accordingly, today the Company sent letters to the SEC, FINRA, and Nasdaq regarding these preliminary findings and requested they open an immediate investigation into the suspected trading activity.
Naked short sales take time to verify, but preliminary financial indicators cause the Company to believe that abusive naked short selling may have occurred. Naked short selling is illegal and damages stockholder value in a company by artificially pushing its stock price down. Common indicators of abusive naked short selling include unusually high trading volume, high financing rates to borrow stock, and persistent failures to deliver that culminate in significant downward pressure on a company's stock price.

Short Sellers

Management

Brag House Launches Investigation Into Suspected Illegal Naked Short Selling, Cites Preliminary Evidence Of Abusive Trading Activity And Urges SEC, FINRA, And Nasdaq To Initiate Immediate Probe Into Unusual Volume, Stock Borrowing Rates, And Price Pressure

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0">Tivic Health&#xAE; Systems, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod&#x2122;, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration.
Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#OTC">SCPX</a>), which will be the primary U.S. manufacturer for Entolimod&#x2122;. Scorpius plans to utilize its scientific and technical expertise to validate the commercial manufacturing process for Tivic's lead candidate, Entolimod&#x2122;.
The GMP Validation Program is valued at approximately $4.1 million and is inclusive of the following activities: cell line verification, legacy process verification, GMP scale-up production, drug product fill and finish, analytical development and qualification, and finally upstream and downstream optimization of the process. All of these activities are designed to ensure Tivic submits to the FDA a complete CMC (chemistry, manufacturing, and control) package for its Entolimod BLA.

SCPX

TIVC

Tivic Health Advances Entolimod Toward FDA BLA Filing With GMP Manufacturing Validation

Wells Fargo analyst Gabe Hajde downgrades Magnera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGN#NYSE">MAGN</a>) from Overweight to Equal-Weight and lowers the price target from $22 to $16.

MAGN

Wells Fargo Downgrades Magnera to Equal-Weight, Lowers Price Target to $16

Press Releases

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Health Care

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Financing

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Comments

Invivyd

Intérêt court

Invivyd (NASDAQ:IVVD) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL